At Pharma Pricing & Market Access Europe 2013, Martin van der Graaff, CVZ gave a presentation entitled "Re-assessing orphan drugs after 4 years of CED"
Download the presentation and learn:
- Problems with Pompe and Fabry re-evaluation after 4 years CED
- "Outcomes" research
- Reassessment woes
- Reimbursement arrangements in some other countries
- Future challenges